Related Experiment Video
Updated: Feb 6, 2026

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
Published on: August 1, 2013
Development of Kasabach-Merritt phenomenon following vaccination: More than a coincidence?
Yi Ji1, Siyuan Chen2, Kaiying Yang1
1Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu, China.
Abstract:
Kasabach-Merritt phenomenon (KMP) occurred uniquely in patients with kaposiform hemangioendothelioma (KHE) and tufted angioma (TA). We report the clinical characteristics of two patients with KHE involving the right upper arm. The patients demonstrated rapid enlargement of the lesion with severe KMP shortly after vaccination. Sirolimus was used to treat the KHE with KMP. The patients showed a quick normalization of the platelet level. The follow-up examination revealed that the size of the mass was significantly decreased. This report raises the intriguing possibility that extrinsic factors may contribute to the development of KMP in the context of an already existing KHE.
Insights
Kasabach-Merritt phenomenon (KMP) in kaposiform hemangioendothelioma (KHE) may be triggered by external factors, such as vaccination. Sirolimus effectively treated KHE with KMP, reducing lesion size and normalizing platelet counts.
Area of Science:
- Vascular Anomalies
- Pediatric Oncology
- Hematology
Background:
- Kasabach-Merritt phenomenon (KMP) is a rare complication associated with kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).
- KMP involves thrombocytopenia, coagulopathy, and consumptive anemia, posing significant clinical challenges.
Observation:
- Two pediatric patients with KHE in the right upper arm presented with rapid lesion enlargement and severe KMP following vaccination.
- The clinical course suggested a potential link between extrinsic factors and KMP development in KHE.
Findings:
- Sirolimus treatment led to rapid normalization of platelet levels in both patients.
- Significant reduction in KHE lesion size was observed after sirolimus therapy.
- These outcomes highlight the efficacy of sirolimus in managing KHE-associated KMP.
Implications:
- The findings suggest that extrinsic factors, possibly including vaccinations, may precipitate KMP in individuals with pre-existing KHE.
- Sirolimus emerges as a promising therapeutic option for KHE with KMP, offering both hematologic and structural improvements.
- Further research is warranted to elucidate the precise mechanisms underlying KMP precipitation and the role of sirolimus in KHE treatment.
Related Concept Videos
Vaccinations
Tip-of-the-Tongue Phenomenon
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Sustainable Development
Development of the Lymphatic System
The first lymph sacs to form are the paired jugular lymph sacs located at the junction of the internal jugular and subclavian veins. From these sacs, lymphatic capillary plexuses extend to the thorax, upper limbs, neck, and head, eventually forming lymphatic vessels. Each jugular lymph sac maintains a...
Language Development
The critical period for language acquisition suggests that the ability to acquire language is at its peak early in life. As people age, this proficiency decreases. Language development begins very...

